Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - ALNYLAM PHARMACEUTICALS, INC. | Financial_Report.xls |
| 10-Q - FORM 10-Q - ALNYLAM PHARMACEUTICALS, INC. | d335938d10q.htm |
| EX-32.1 - SECTION 906 CEO CERTIFICATION - ALNYLAM PHARMACEUTICALS, INC. | d335938dex321.htm |
| EX-31.1 - SECTION 302 CEO CERTIFICATION - ALNYLAM PHARMACEUTICALS, INC. | d335938dex311.htm |
| EX-10.2 - LEASE ENTERED INTO AS OF FEBRUARY 10, 2012 - ALNYLAM PHARMACEUTICALS, INC. | d335938dex102.htm |
| EX-10.1 - 2012 ANNUAL INCENTIVE PROGRAM - ALNYLAM PHARMACEUTICALS, INC. | d335938dex101.htm |
| EX-31.2 - SECTION 302 CFO CERTIFICATION - ALNYLAM PHARMACEUTICALS, INC. | d335938dex312.htm |
| EX-32.2 - SECTION 906 CFO CERTIFICATION - ALNYLAM PHARMACEUTICALS, INC. | d335938dex322.htm |
Exhibit 12
STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS/DEFICIENCIES TO FIXED CHARGES
(dollars in thousands)
| Three Months ended March 31, 2012 |
Fiscal Year Ended December 31, | |||||||||||||||||||||||
| 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||||
| Earnings (loss): |
||||||||||||||||||||||||
| Pre-tax loss from continuing operations before adjustment for loss from equity investee |
$ | (10,479 | ) | $ | (54,144 | ) | $ | (35,362 | ) | $ | (42,098 | ) | $ | (16,240 | ) | $ | (79,146 | ) | ||||||
| add: Fixed charges (see below) |
285 | 1,207 | 1,207 | 712 | 1,115 | 1,553 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Pre-tax income (loss) from continuing operations before adjustment for income/loss from equity investees plus fixed charges |
$ | (10,194 | ) | $ | (52,937 | ) | $ | (34,155 | ) | $ | (41,386 | ) | $ | (15,125 | ) | $ | (77,593 | ) | ||||||
| Fixed charges: |
||||||||||||||||||||||||
| Interest expense on indebtedness |
$ | — | $ | — | $ | — | $ | — | $ | 872 | $ | 1,083 | ||||||||||||
| Interest expense on portion of rent expense representative of interest |
285 | 1,207 | 1,207 | 712 | 243 | 470 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total fixed charges |
$ | 285 | $ | 1,207 | $ | 1,207 | $ | 712 | $ | 1,115 | $ | 1,553 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Ratio of earnings to fixed charges |
— | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Deficiency of earnings available to cover fixed charges |
$ | (10,479 | ) | $ | (54,144 | ) | $ | (35,362 | ) | $ | (42,098 | ) | $ | (16,240 | ) | $ | (79,146 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||